Creekridge Capital, a healthcare and technology vendor leasing company based in Minneapolis, announced Scott Preiser as sales manager in the ophthalmology market.
Ophthalmology
Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island injected a patient suffering from vitreo-macular adhesion with JETREA, a dilution of ocriplasmin that is the first FDA approved drug to treat VMA, according to a report by the Times Union.
Avedro, a medical device and pharmaceutical company based in Waltham, Mass., has received $43 million in Series D funding from investment group Abingworth and investment adviser Third Point.
Jonathan H. Talamo, MD, medical director of SurgiSite Boston, performed the first cataract surgery utilizing the Catalys Precision Laser System to be done in Massachusetts.
Researchers of Miller School of Medicine in Miami worked with an international team to identify seven new genes that can be linked to macular degeneration in a study entitled "Seven New Loci Associated with Age-Related Macular Degeneration," according to a…
Advertisement
Ryan D. Walsh, MD, board certified neurologist, has been named Assistant Professor of Ophthalmology and Neurology at the Medical College of Wisconsin and will practice at the Froedtert & The Medical College of Wisconsin Eye Institute, according to a Wauwatosa…
Markets and Markets published a market research report that found the optical imaging technologies to be worth nearly $916 million in 2012 and estimated that by 2018 the market's value will reach $1.9 billion, according to a Herald Online report.
IREDEX, laser-based medical systems developer and manufacturer, has announced that its ophthalmology revenues in the fourth quarter of 2012 were $9.2 million, up from $8.6 million in the fourth quarter of 2011, a nearly 7 percent increase, according to a…
NY Vision Group, offering comprehensive ophthalmologic services, is opening a location led by board-certified ophthalmologist Harry Kostner, MD, in the New York City neighborhood of Tribeca, according to a Tribeca Citizen report.
Transcend Medical, a Menlo Park, Calif.-based device company focused on minimally invasive treatments for glaucoma patients, has joined the randomized, multicenter, prospective, controlled COMPASS trial that is studying the CyPass Micro-Stent.